✦ LIBER ✦

Challenges of phase III trial design for novel treatments in diseases with no standard treatment: The AZA-001 myelodysplasia study model

✍ Scribed by Fenaux, Pierre; Seymour, John F.; Santini, Valeria; Silverman, Lew; Gore, Steven; List, Alan; Sanz, Guillermo; Mufti, Ghulam J.; Estey, Eli; Swern, Arlene S.; Beach, C.L.; Hellstrom-Lindberg, Eva

Book ID: 122259025
Publisher: Elsevier Science
Year: 2014
Tongue: English
Weight: 492 KB
Volume: 38
Category: Article
ISSN: 0145-2126
DOI: 10.1016/j.leukres.2013.10.014

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Efficient design of a phase III trial of

Efficient design of a phase III trial of competing tests for personalised cancer treatment in the absence of gold standard outcome data: challenges and potential solutions

✍ Peter Hall,Christopher McCabe,Claire Hulme,Richard Edlin,Janet Dunn… 📂 Article 📅 2013 🏛 BioMed Central 🌐 English ⚖ 112 KB

Treatment Rationale Study Design for the

Treatment Rationale Study Design for the MetLung Trial: A Randomized, Double-Blind Phase III Study of Onartuzumab (MetMAb) in Combination With Erlotinib Versus Erlotinib Alone in Patients Who Have Received Standard Chemotherapy for Stage IIIB or IV Met-Positive Non–Small-Cell Lung Cancer

✍ David R. Spigel; Martin J. Edelman; Tony Mok; Kenneth O'Byrne; Luis Paz-Ares; We 📂 Article 📅 2012 🏛 CIG Media Group, LP. 🌐 English ⚖ 255 KB